Researchers sought to assess patients’ understanding of the systemic nature of psoriatic disease.
Researchers evaluated the association between biological therapy and the time to incident inflammatory psoriatic arthritis.
Researchers assessed the accuracy of a traditional statistical risk factor-based model versus machine learning in predicting the 5-year probability of biologic discontinuation.
Researchers assessed whether biologics reduce the incidence of psoriatic arthritis among patients with psoriasis.
Researchers sought to investigate the effect of targeted therapies on cardiovascular risk in psoriasis and psoriatic arthritis.
People with psoriasis have double the odds of celiac disease vs people without psoriasis.
Study investigators assessed the risk of infection among pediatric patients undergoing treatment with methotrexate, etanercept, or ustekinumab for psoriasis.
A team of investigators sought to determine whether alcohol consumption or cigarette smoking contributed to the risk of developing psoriasis among postmenopausal women.
Investigators sought to determine what effect the COVID-19 pandemic had on patient preference for biologic treatment for psoriasis.
The researchers sought to evaluate whether there was an association between the presence of psoriasis and concomitant psoriatic arthritis and comorbidity burden and treatment outcomes.
The effectiveness and safety profile of brodalumab during a period of 104 weeks in everyday practice are reported.
Does systemic agent prescribing for psoriasis vary by season or other exacerbating factors?
Investigators sought to elucidate the prevalence of anxiety and depression in patients with pediatric psoriasis and advocate for psychological screening and intervention as needed.
A GRAPPA working group highlighted the importance of screening for comorbidities to guide treatment selection among patients with psoriatic arthritis.
The efficacy, safety, pharmacokinetics, and immunogenicity of adalimumab combined with MTX compared with that adalimumab in patients with chronic plaque psoriasis is evaluated.
Investigators sought to evaluate the association between COVID-19 infection and persistent or new-onset rash following infection.
Updated GRAPPA psoriatic arthritis treatment recommendations now include the use of biosimilars and the tapering of therapy.
AMA president Jack Resneck, Jr., MD, and dermatologist David M. Pariser, MD, FAAD, tell us their thoughts and experiences on the challenges patients face in accessing methotrexate for psoriasis and other autoimmune diseases.
Researchers sought to evaluate the impact of risankizumab vs placebo on health care-related quality of life and other patient-reported outcomes in patients with psoriatic arthritis.
A survey reveals the extent of implementation of recommendations for the treatment of psoriasis in patients of reproductive age.